Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study

BACKGROUND: We investigated the efficacy and safety of apararenone (MT-3995), a non-steroidal compound with mineralocorticoid receptor agonist activity, in patients with stage 2 diabetic nephropathy (DN). METHODS: The study had two parts: a dose–response, parallel-group, randomized, double-blind, pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wada, Takashi, Inagaki, Masaya, Yoshinari, Toru, Terata, Ryuji, Totsuka, Naoko, Gotou, Miki, Hashimoto, Gaia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880964/
https://www.ncbi.nlm.nih.gov/pubmed/32974732
http://dx.doi.org/10.1007/s10157-020-01963-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880964/
https://www.ncbi.nlm.nih.gov/pubmed/32974732
http://dx.doi.org/10.1007/s10157-020-01963-z

Ejemplares similares